louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05287724: Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
Official title: Pilot Studies Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Pruritus
Skin Disorder
Lead sponsor: Wright State University
Sponsor class: OTHER
First posted: 2022-03-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this double-blinded placebo-controlled cross-over study is to define the role of the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of pruritus (skin itching). The study is designed to have all subjects treated with a seven-day regimen of both NAC and placebo. NAC will be prescribed at a dose of 1,500 mg twice daily for seven days. Subjects will initially be randomly assigned (1:1) to either the NAC or placebo arm of the study, before crossing over to the opposite arm after completing a minimum of 30-day washout period. The study will encompass a period of approximately 11 weeks (about 2 and a half months).


Eligibility criteria: Inclusion Criteria:

* Males and Females
* All skin types (Fitzpatrick types I - VI)
* Age 18 - 40
* Able to comprehend procedures and risks

Exclusion Criteria:

* Currently taking immunosuppressive or immunomodulating or psychotropic medications.

This includes antihistamines and aspirin-like anti-inflammatory medications (NASIDs) for the past month.

* History of peripheral neuropathy, Charcot-Marie-Tooth, familial dysautonomia or heavy metal toxicity
* History of gastrointestinal abnormalities (including irritable bowel syndrome)
* History of inadequately controlled Diabetes Mellitus
* History of abnormal scarring
* History of skin infections within 6 weeks
* History of skin disease (atopic dermatitis, psoriasis, xerosis) or "sensitive skin"
* Pregnancy or nursing
* Other serious health issues, including liver or kidney disease

Primary outcomes:
measure: Change in pain level from baseline with NAC.
timeFrame: 7 days
measure: Change in pain level from baseline with placebo.
timeFrame: 7 days
measure: Change in itch level from baseline with NAC.
timeFrame: 7 days
measure: Change in itch level from baseline with placebo.
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Fairborn
country: United States
facility: Wright State Physicians
state: Ohio
Study officials:
affiliation: Wright State University
name: Craig Rohan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03248024: An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital
Official title: Etude Des Facteurs Explicatifs Des Coûts de la Prise En Charge Des Patients Adultes Atteints d'Une MICI Suivis au CHRU de Nancy et traités Par biothérapie
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inflammatory Bowel Diseases
Keywords: Chronic Disease
Ulcerative Colitis
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
Collaborators: name: HEVA - Lyon
First posted: 2017-08-14
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who received biotherapy during the last 12 months preceeding consultation for treatment of crohn's disease or ulcerative colitis.

Brief summary: The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or adalimumab), including biosimilars (infliximab biosimilars: Inflectra ™ and Remsima ™) for treating Crohn's desease or ulcerative colitis


Eligibility criteria: Inclusion Criteria:

1. Patients consulted at the Gastroenterology services of Nancy University Hospital during the period of inclusion
2. Patients over 18 of age the day of consultation
3. Patients treated at least one time by biotherapy during the last 12 months preceeding inclusion
4. Patients with crohn's disease or ulcerative colitis.
5. Patients accepting to respond to the questionnary

Exclusion Criteria:

* Age under 18 years , the day of consultation
* Patient that not accept or unable to complete the retrospective questionnary

Primary outcomes:
measure: Retrospective health care consumption
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02071524: Evaluation of the Effects of Fluid Therapy on Respiratory Mechanics
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mechanical Ventilation Complication
Actual Impaired Fluid Volume
Lead sponsor: Università degli Studi di Ferrara
Sponsor class: OTHER
First posted: 2014-02-26
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators hypothesize that large doses of fluids used during intraoperative could affect lung parenchyma structure and, consequently, gas exchange and respiratory mechanics. The purpose of this study is to evaluate fluids effects on oxygenation, respiratory mechanics, by using two different solutions: crystalloid or colloid.

Detailed description: Inclusion Criteria:

* patients undergoing elective abdominal, thoracic, vascular surgery
* minimum age 18 years
* informed consent

Exclusion Criteria:

* patients with severe cardiomyopathy or severe heart failure
* history of coagulation disorders
* patients with severe cardiovascular or respiratory disorders
* renal insufficiency

Respiratory mechanic parameters (i.e., inspiratory peak pressure, plateau pressure, total airway resistance, and static compliance) are obtained .Blood samples are drawn simultaneously from the arterial catheters for gas analysis. Data were collected after induction of anesthesia (T0) after 1 h (T1), 2 h (T2), 3 h (T3) and at the end of surgery.

Primary outcome: evaluate the fluids effects on oxygenation, respiratory mechanics

Secondary outcome: Incidence of surgery related complications

Eligibility criteria: Inclusion Criteria:

* patients undergoing elective abdominal, thoracic, vascular surgery
* minimum age 18 years
* informed consent

Exclusion Criteria:

* patients with severe cardiomyopathy or severe heart failure
* history of coagulation disorders
* patients with severe cardiovascular or respiratory disorders
* renal insufficiency
* severe liver diseases

Primary outcomes:
measure: effects on oxygenation, respiratory mechanics
timeFrame: every 30 minutes till the end of surgery
Secondary outcomes:
measure: Incidence of respiratory complications
timeFrame: 28 days
Other outcomes:
Locations:
city: Ferrara
country: Italy
facility: University of Ferrara
Study officials:
References:
Clinical trial NCT01221324: Diagnostic Value of C-reactive Protein and White Blood Cell Counts for Early Detection of Inflammatory Complications After Open Resection of Colorectal Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Given Indication for Open Resection of Colorectal Cancer
Lead sponsor: Cantonal Hospital of St. Gallen
Sponsor class: OTHER
First posted: 2010-10-15
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Given indication for resection of colorectal cancer

Brief summary: Although widely used, there is a lack of evidence concerning diagnostic value of C-reactive protein (CRP) and white blood cell counts (WBC) in the postoperative course. The aim of this study was to evaluate the diagnostic accuracy of CRP and WBC for postoperative inflammatory complications after open resection of colorectal cancer.


Eligibility criteria: Inclusion Criteria:

* all patients with resection of colorectal cancer

Exclusion Criteria:

* lack of measurement of C-reactive protein
* lack of measurement of white blood cell counts

Primary outcomes:
measure: postoperative inflammatory complications
timeFrame: 30 days
Secondary outcomes:
measure: Anastomotic leakage
timeFrame: 60 days
Other outcomes:
Locations:
Study officials:
affiliation: Cantonal Hospital St. Gallen
name: Rene Warschkow, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Warschkow R, Tarantino I, Torzewski M, Naf F, Lange J, Steffen T. Diagnostic accuracy of C-reactive protein and white blood cell counts in the early detection of inflammatory complications after open resection of colorectal cancer: a retrospective study of 1,187 patients. Int J Colorectal Dis. 2011 Nov;26(11):1405-13. doi: 10.1007/s00384-011-1262-0. Epub 2011 Jun 24.
Clinical trial NCT00593424: Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins
Official title: Effect of Changing the Diet to Low Fat/High Carbohydrate or High Monounsaturated Fat/Low Carbohydrate on Fasting and Post Fat Load Lipoproteins of Diabetics With Moderate Hypertriglyceridemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertriglyceridemia
Diabetes Mellitus
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2008-01-15
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study examines the effect of two diets on fasting and post fat load lipoproteins of subjects with type 2 diabetes with moderate hypertriglyceridemia.


Eligibility criteria: Inclusion Criteria:

* Male and female,
* 18 - 75 years of age
* Type 2 diabetes
* Fasting triglycerides 300 -800mg/dL

Primary outcomes:
measure: Paired t-test or Wilcoxon signed rank test will be used to evaluate the change in fasting triglycerides with the diets.
timeFrame: At the beginning and end of each of the two diet regimens
Secondary outcomes:
measure: Post-prandial lipids will be evaluated by t-test or Wilcoxon signed rank test for AUC of triglyceride and remnant lipoprotein measured by immunoseparation.
timeFrame: At the beginning and end of each of the two diet regimens
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Central Arkansas Veterans Healthcare System
state: Arkansas
Study officials:
affiliation: UAMS/CAVHS
name: Debra L Simmons, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02209324: Open-label Study of ASP2151 in Herpes Simplex Patients
Official title: Open-label Study of ASP2151 in Herpes Simplex Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Herpes Simplex
Lead sponsor: Maruho Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2014-08-05
Enrollment: 275
Sex: ALL
Minimum age (years): 16
Maximum age (years): 79
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A multicenter, open-label study is conducted to evaluate the efficacy and safety of ASP2151 in patients with herpes simplex (recurrent labial/facial herpes and recurrent genital herpes and Kaposi varicelliform).


Eligibility criteria: Inclusion Criteria:

1. Patients with a rash associated with herpes simplex and a recurrent episode meeting the following criteria

   * Recurrent labial/facial herpes: Patients with at least 10 papulae or vesicles/pustules
   * Recurrent genital herpes: Patients with at least 5 papules or vesicles/pustules on the genital organs or in the genital and circumanal region
   * Kaposi varicelliform eruption: Patients with major skin symptoms of papulae or vesicles
2. Patients who can start receiving the study drug within 48 hours after onset of rash
3. Age: 16 years or older, but younger than 80 years

Exclusion Criteria:

1. Patients who are not expected to have an adequate response to oral antiviral medication.
2. Patients with two or more types of herpes simplex.
3. An extreme decline in immune function
4. Presence of serious complications
5. Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent:

   * AST or ALT ≥ 2.5 x upper limit of normal
   * Platelet count \< lower limit of normal
   * Serum creatinine ≥ 1.5 mg/dL
   * Creatinine clearance \< 30 mL/min
6. Current or previous history of malignant tumor within 5 years before informed consent
7. Diagnosis of autoimmune disease

Primary outcomes:
measure: Percentage of Participants With Healing by Day 8
timeFrame: 8 days
Secondary outcomes:
measure: Time to Healing
timeFrame: 29 days
measure: Time to Complete Crusting
timeFrame: 29 days
measure: Time to Virus Disappearance
timeFrame: 29 days
Other outcomes:
Locations:
city: Sapporo
country: Japan
facility: Sapporo Hokkaido Japan
city: Tokyo
country: Japan
facility: Oota-ku Tokyo Japan
city: Yokohama
country: Japan
facility: Yokohama Kanagawa Japan
Study officials:
References:
Clinical trial NCT00898924: Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
Official title: Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Keywords: stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
Lead sponsor: Alliance for Clinical Trials in Oncology
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2009-05-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with stage III non-small cell lung cancer.

Brief summary: RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations and k-ras oncogene mutations in patients with stage III non-small cell lung cancer.

Detailed description: OBJECTIVES:

* Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
* Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response to treatment in these patients.

OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras mutations.

Eligibility criteria: Inclusion criteria:

1. Eligible patients had histologic documentation of un- treated stage III NSCLC.
2. Radiation oncologist confirmation was required that radiation could be given per protocol.
3. Eastern Cooperative Group Criteria Performance Status of 0 to 2
4. Tumor specimen paraffin block or unstained slides and standard initial laboratory tests
5. Signed institutional review board-approved, protocol-specific in- formed consent in accordance with federal and institutional guidelines

Exclusion criteria:

1. Patients with scalene, supraclavicular, or contralateral hilar lymph node involvement, or direct invasion of the vertebral body or with a pleural effusion were ineligible.

Primary outcomes:
measure: Overall survival
timeFrame: Up to 3 years
measure: Progression free survival
timeFrame: Up to 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Pasi Janne, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06266624: Tourniquet-Test in HHT
Official title: Tourniquet-Test in HHT
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: HHT
Keywords: HHT
Tourniquet Test
Lead sponsor: University Hospital, Essen
Sponsor class: OTHER
First posted: 2024-02-20
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

Detailed description: The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

Eligibility criteria: Inclusion Criteria:

* In patients with confirmed HHT diagnosis (≥ 3 Curaçao criteria or positive molecular genetics)
* aged over 18 years

Exclusion Criteria:

* if inclusion criteria does not apply

Primary outcomes:
measure: number of positive Tourniquet Test results in HHT patients
timeFrame: three years
Secondary outcomes:
Other outcomes:
Locations:
city: Essen
country: Germany
facility: University Hospital Essen
state: Nordrhein Westphalen
Study officials:
References:
Clinical trial NCT06349824: Dextrose, Steroid, PRP: Choosing the Right Injection for CRS Relief; a RCT
Official title: Dextrose, Steroid, PRP: Choosing the Right Injection for Long Term CRS Relief; a RCT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Carpal Tunnel Syndrome
Lead sponsor: Sheikh Zayed Medical College
Sponsor class: OTHER_GOV
First posted: 2024-04-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: USG guided injections to relieve carpal tunnel syndrome with dextrose water or steroid or PRP


Eligibility criteria: Inclusion Criteria:

* NA

Exclusion Criteria:

* Na

Primary outcomes:
measure: VAS
timeFrame: five to six months
Secondary outcomes:
Other outcomes:
Locations:
city: Rahim yar khan
country: Pakistan
facility: Sheikh Zayed Medical College
state: Punjab
Study officials:
affiliation: sheikh zayed medical college rhaim yar khan
name: sairah sadaf
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00607516: Radiostereometric Analysis of Acetabular Wear and Periprosthetic Bone Mineral Density Changes in Hemiarthroplasties
Official title: Radiostereometric Analysis of Acetabular Wear and Periprosthetic Bone Mineral Density Changes in Cemented and Uncemented Hemiarthroplasties for Femoral Neck Fractures
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Femoral Neck Fractures
Bone Density
Acetabular Wear
Hemiarthroplasty
Keywords: fracture
arthroplasty
wear
osteoporosis
bone
Lead sponsor: Ullevaal University Hospital
Sponsor class: OTHER
First posted: 2008-02-05
Enrollment: 22
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Substudy and continuation of HEMI-SAB-UUS (NCT00491673)

Study on radiostereometric measurements of acetabular wear in bipolar hemiarthroplasties and measurements of periprosthetic bone mineral density in cemented and uncemented hemiarthroplasties in patients with femoral neck fractures.

Null hypothesis: No difference in acetabular wear or in bone mineral density changes between cemented and uncemented hemiarthroplasties

Detailed description: Patients are randomised to treatment with cemented or uncemented bipolar hemiarthroplasty. 1mm tantalum markers are inserted in the pelvis during surgery. RSA X-rays and DEXA measurements conducted postoperatively, after 3 and 12 months. Follow-up visits and clinical examination at 3 and 12 months.

Eligibility criteria: Inclusion Criteria:

* Femoral neck fracture
* 65 years or older
* Able to walk independently

Exclusion Criteria:

* Cognitive dysfunction
* Infection
* Fracture caused by malignant disease

Primary outcomes:
measure: Acetabular wear in mm
timeFrame: 1 year
measure: Loss of bone mineral density (BMD)
timeFrame: 1 year
Secondary outcomes:
measure: Functional outcome including pain (Harris Hip Score)
timeFrame: 1 year
measure: Activities Of Daily Living (Barthels ADL-Index)
timeFrame: 1 year
measure: Quality Of Life (EQ-5D)
timeFrame: 1 year
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Ullevål University Hospital
Study officials:
affiliation: Ullevål University Hospital, University of Oslo
name: Lars Nordsletten, Prof MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01902316: Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus
Official title: Clinical Verification for Early Diagnosis of Type 2 Diabetes Mellitus by Standard-Free, Label-Free LC-MS/MS Quantification of Glycated Peptides
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 2
Keywords: Type 2 Diabetes Mellitus
peptide biomarker
early diagnosis
label free
Lead sponsor: Beijing Institute of Technology
Sponsor class: OTHER
First posted: 2013-07-18
Enrollment: 389
Sex: ALL
Minimum age (years): 35
Maximum age (years): 72
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: university hospital, plasma samples of physical examination, faculties and staff of a certain university

Brief summary: Although diabetes has been controlled since insulin became available, it is still considered incurable and poses serious threats to human health. Reports have suggested that the hyperglycemic condition of patients with diabetes mellitus may be greatly alleviated or even reversed if it could be controlled at an early stage of diabetes. Thus, early detection and diagnosis of diabetes and prediabetes are become increasingly important in the treatment and prevention of diabetes. Diabetes mellitus is currently diagnosed by recurrent or persistent hyperglycemia. In an effort to identify novel biomarkers for diabetes, research has shown that neither plasma glucose nor glycated hemoglobin (HbA1c) levels are unable to be used in the early detection of diabetes. In this work, the investigators have found 8 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference between normal people and diabetes patients.

Detailed description: The procedure of clinical study was:

1. to get plasma samples from hospital;
2. digestion of plasma protein-mixture by trypsin;
3. run mass spectrometry and monitor the amount of target HSA-peptides.

Eligibility criteria: Inclusion Criteria:

* Type 2 Diabetes Mellitus cases;
* Impaired Glucose Tolerance cases;
* Normal Glucose Tolerance cases

Exclusion Criteria:

* Type 1 Diabetes Mellitus cases;
* Gestational Diabetes Mellitus cases;
* Hepatitis patients

Primary outcomes:
measure: measurement of the amount of plasma peptides
timeFrame: two years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: School of Life Science, BIT
name: Yulin Deng, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: